2-tert-Butyl-5-chloro-1,3-dimethylbenzene | 116384-66-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-tert-Butyl-5-chloro-1,3-dimethylbenzene
• CAS: 116384-66-8
• 化学式: C₁₂H₁₇Cl
• 分子量: 196.71
• InChiKey: JYQTWYUHXPGTMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• OPIOID RECEPTOR MODULATORS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170056377A1

  公开（公告）日：2017-03-02

  Disclosed is an in vitro screening method for identifying an antagonist-to-agonist allosteric modifier of a mu-opioid receptor and an in vivo method for confirming that a test compound is such a modifier of a mu-opioid receptor. Also disclosed is a method for treating an opioid receptor-associated condition using a compound of Formula (I) and a pharmaceutical composition containing the same.

  揭示了一种体外筛选方法，用于识别μ-阿片受体的拮抗剂-激动剂异位调节剂，并揭示了一种体内方法，用于确认测试化合物是否为μ-阿片受体的这种调节剂。还揭示了一种使用式（I）化合物和含有该化合物的药物组合物治疗阿片受体相关疾病的方法。
• Compounds targeting proteins, compositions, methods, and uses thereof
  申请人：BioTheryX, Inc.

  公开号：US10040804B2

  公开（公告）日：2018-08-07

  The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

  本发明提供了调节蛋白质功能的化合物，以恢复蛋白质的平衡，包括细胞因子、CK1α、GSPT1、aiolos 和/或 ikaros 活性以及细胞-细胞粘附性。本发明提供了调节蛋白质介导的疾病，如细胞因子介导的疾病、失调、病症或反应的方法。本发明提供了组合物，包括与其他细胞因子和炎症介质的组合物。提供了治疗、改善或预防与蛋白质相关的疾病、失调或病症的方法，例如与细胞因子相关的疾病、失调和病症，包括炎症、纤维肌痛、类风湿性关节炎、骨关节炎、强直性脊柱炎、银屑病、银屑病关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺病、慢性阻塞性肺病、阿尔茨海默病和癌症。
• Combination therapy for treatment of cancer
  申请人：G1 Therapeutics, Inc.

  公开号：US11364222B2

  公开（公告）日：2022-06-21

  Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.

  由式D的CDK4/6抑制剂与式A、B或C的选择性雌激素受体下调剂组成的组合物、组合物和方法，有利于治疗异常细胞增殖，包括癌症或肿瘤。
• Z-SELECTIVE OLEFIN METATHESIS CATALYSTS AND THEIR SYNTHETIC PROCEDURE
  申请人：Endo Koji

  公开号：US20140106960A1

  公开（公告）日：2014-04-17

  The invention relates to C—H activated olefin metathesis catalyst compounds, the preparation of such compounds, and the use of such catalysts in the metathesis of olefins and olefin compounds, more particularly, the use of such catalysts in Z selective olefin metathesis reactions. In general, the catalyst compounds of the invention comprise a Group 8 metal (M), an alkylidene moiety (═CR 1 R 2 ), or more generally (═(C) m CR 1 R 2 ), an anionic ligand (X 1 ), two or three neutral ligands (L 1 , L 2 , and L 3 ) and a 2-electron anionic donor bridging moiety (Q*) that forms a chelate ring structure in conjunction with L1 and M. Such catalysts generally correspond to the formula X 1 (L 3 ) k L 2 L 1 Q*M=(C) m CR 1 R 2 , wherein X1 is any anionic ligand, L 1 , L 2 , and L 3 are, independently, any neural electron donor ligand, k is 0 or 1, m is 0, 1, or 2, Q* is a 2-electron anionic donor bridging moiety linking L 1 and M, M is a Group 8 transition metal, and R 1 and R 2 are, independently, hydrogen, hydrocarbyl, substituted hydrocarbyl, heteroatom-containing hydrocarbyl, substituted heteroatom-containing hydrocarbyl, or functional groups. The invention has utility in the fields of catalysis, organic synthesis, polymer chemistry, and industrial and fine chemicals chemistry.
• COMBINATION THERAPY FOR TREATMENT OF CANCER
  申请人：G1 Therapeutics, Inc.

  公开号：US20190321332A1

  公开（公告）日：2019-10-24

  Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.